REDUCE-IT Trial Studying Icosapent Ethyl: An In-Depth Review of USA Dataset with Commentary
Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC
Guest: Roger Blumenthal, MD
Guest: Robert H. Eckel, MD
Guest: Peter Libby, MD
Guest: R. Preston Mason, PhD
Guest: P. Gabriel Steg, MD
Join an internationally recognized panel of experts as they provide a comprehensive review and commentary of the results from the REDUCE-IT trial, which studied the effect of icosapent ethyl on cardiovascular outcomes. The expert panel also offers insights and pearls on how these results affect clinical lipid management in patients at risk for ASCVD, especially after the FDA expanded the indication of icosapent ethyl to include the reduction of ASCVD events.
| Time | Topic | Format |
| 16 minutes | REDUCE-IT USA Subgroup Analysis | Audio over slides |
| 7 minutes | Panel Discussion 1 and Q&A | Audio |
| 8 minutes | Panel Discussion 2 | Video |